Digestive Disease Interventions 2023; 07(01): 051-057
DOI: 10.1055/s-0042-1760425
Review Article

Inflammatory Bowel Disease and Colorectal Cancer

Tamara Glyn
1   Department of Surgery, Christchurch Hospital, Christchurch, New Zealand
2   Department of Surgery, University of Otago, Otago, New Zealand
Amy L. Lightner
3   Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio
› Author Affiliations
Funding None.


The prevalence of inflammatory bowel disease (IBD) continues to rise with the increasing rates in the developing world and the improving longevity of IBD patients. A diagnosis of colonic IBD is associated with an increased risk of colorectal cancer (CRC) and this accounts for approximately 15% of the estimated mortality from IBD. CRC in IBD appears to be a pathologically distinct entity and progress is being made to understand the unique components of this process with a view to better predicting outcomes and potentially improving surveillance, treatments, and eventually modifying risk. In the interim, patients are entered into surveillance programs designed to identify at-risk patients early and improve outcomes. Dramatic evolution of technology in this area has changed the landscape of surveillance and dysplasia management over the last decade and promises to continue to do so. This review aims to provide a contemporary overview of IBD-associated CRC in terms of its epidemiology, pathogenesis, surveillance, and management.

Publication History

Received: 01 December 2022

Accepted: 05 December 2022

Article published online:
19 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220-228
  • 2 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48 (04) 526-535
  • 3 Lakatos L, Mester G, Erdelyi Z. et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12 (03) 205-211
  • 4 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10 (06) 639-645
  • 5 Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91 (04) 854-862
  • 6 Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23 (08) 1097-1104
  • 7 Gatenby G, Glyn T, Pearson J, Gearry R, Eglinton T. The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. Colorectal Dis 2021; 23 (09) 2399-2406
  • 8 Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81 (03) 489-501.e26
  • 9 Magro F, Gionchetti P, Eliakim R. et al; European Crohn's and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn's Colitis 2017; 11 (06) 649-670
  • 10 Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 2021; 161 (03) 1043-1051.e4
  • 11 Wilks S. Morbid appearances in the intestine of Miss Bankes. Med Times Gazette 1859; 2 (02) 264-265
  • 12 Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. J Am Med Assoc 1932; 99 (16) 1323-1329
  • 13 Ng SC, Shi HY, Hamidi N. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390 (10114): 2769-2778
  • 14 Molodecky NA, Soon IS, Rabi DM. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142 (01) 46-54.e42 , quiz e30
  • 15 Yang S-K, Yun S, Kim J-H. et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008; 14 (04) 542-549
  • 16 Manninen P, Karvonen A-L, Huhtala H. et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohn's Colitis 2013; 7 (11) e551-e557
  • 17 Tranter-Entwistle I, Mullaney TG, Noah K. et al. Long-term incidence of dysplasia and colorectal cancer in an ulcerative colitis population-based cohort. ANZ J Surg 2020; 90 (05) 821-825
  • 18 Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience. Ann Surg 2010; 252 (02) 330-335
  • 19 Jewel Samadder N, Valentine JF, Guthery S. et al. Colorectal cancer in inflammatory bowel diseases: a population-based study in Utah. Dig Dis Sci 2017; 62 (08) 2126-2132
  • 20 Najafimehr H, Aghdaei HA, Pourhoseingholi MA. et al. A systematic review and meta-analysis on the association between inflammatory bowel disease family history and colorectal cancer. Gastroenterol Res Pract 2021; 2021: 4874459
  • 21 Allende D, Elmessiry M, Hao W. et al. Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings. Colorectal Dis 2014; 16 (09) 710-718 , discussion 718
  • 22 Driessen A, Macken E, Moreels T, Jouret-Mourin A. Dysplasia in inflammatory bowel disease. Acta Gastroenterol Belg 2017; 80 (02) 299-308
  • 23 Kabir M, Fofaria R, Arebi N. et al. Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). Aliment Pharmacol Ther 2020; 52 (01) 5-19
  • 24 Fogt F, Vortmeyer AO, Goldman H, Giordano TJ, Merino MJ, Zhuang Z. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 1998; 29 (02) 131-136
  • 25 Robles AI, Traverso G, Zhang M. et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology 2016; 150 (04) 931-943
  • 26 Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci 2018; 25 (01) 79
  • 27 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319 (09) 525-532
  • 28 Umetani N, Sasaki S, Watanabe T. et al. Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. Jpn J Cancer Res 1999; 90 (10) 1081-1087
  • 29 Sato A, MacHinami R. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int 1999; 49 (10) 858-868
  • 30 Burmer GC, Rabinovitch PS, Haggitt RC. et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103 (05) 1602-1610
  • 31 Liu X, Goldblum JR, Zhao Z. et al. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. Am J Surg Pathol 2012; 36 (08) 1228-1233
  • 32 Lamb CA, Kennedy NA, Raine T. et al; IBD Guidelines eDelphi Consensus Group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68 (Suppl. 03) s1-s106
  • 33 Tytgat GNJ, Dhir V, Gopinath N. Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Eur J Cancer 1995; 31A (7-8): 1174-1177
  • 34 Moussata D, Allez M, Cazals-Hatem D. et al; The GETAID. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. Gut 2018; 67 (04) 616-624
  • 35 Chiu K, Riddell RH, Schaeffer DF. DALM, rest in peace: a pathologist's perspective on dysplasia in inflammatory bowel disease in the post-DALM era. Mod Pathol 2018; 31 (08) 1180-1190
  • 36 Carballal S, Maisterra S, López-Serrano A. et al; EndoCAR Group of the Spanish Gastroenterological Association and Spanish Digestive Endoscopy Society. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 2018; 67 (01) 70-78
  • 37 Alexandersson B, Hamad Y, Andreasson A. et al. High-definition chromoendoscopy superior to high-definition white-light endoscopy in surveillance of inflammatory bowel diseases in a randomized trial. Clin Gastroenterol Hepatol 2020; 18 (09) 2101-2107
  • 38 Wan J, Wang X, Yang ZP, Wu KC. Systematic review with meta-analysis: chromoendoscopy versus white light endoscopy in detection of dysplasia in patients with inflammatory bowel disease. J Dig Dis 2019; 20 (04) 206-214
  • 39 Iacucci M, Kaplan GG, Panaccione R. et al. A randomized trial comparing high definition colonoscopy alone with high definition dye spraying and electronic virtual chromoendoscopy for detection of colonic neoplastic lesions during IBD surveillance colonoscopy. Am J Gastroenterol 2018; 113 (02) 225-234
  • 40 Bessissow T, Dulai PS, Restellini S. et al. Comparison of endoscopic dysplasia detection techniques in patients with ulcerative colitis: a systematic review and network meta-analysis. Inflamm Bowel Dis 2018; 24 (12) 2518-2526
  • 41 Hu AB, Burke KE, Kochar B, Ananthakrishnan AN. Yield of random biopsies during colonoscopies in inflammatory bowel disease patients undergoing dysplasia surveillance. Inflamm Bowel Dis 2021; 27 (06) 779-786
  • 42 Ahmed T, Monti J, Lashner B. Random versus targeted biopsies for colorectal cancer surveillance in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2010; 6 (07) 438-442
  • 43 Watanabe T, Ajioka Y, Mitsuyama K. et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 2016; 151 (06) 1122-1130
  • 44 Soetikno R, East J, Suzuki N. et al. Endoscopic submucosal dissection for nonpolypoid colorectal dysplasia in patients with inflammatory bowel disease: in medias res. Gastrointest Endosc 2018; 87 (04) 1085-1094
  • 45 Lord R, Burr NE, Mohammed N, Subramanian V. Colonic lesion characterization in inflammatory bowel disease: a systematic review and meta-analysis. World J Gastroenterol 2018; 24 (10) 1167-1180
  • 46 Iacucci M, McQuaid K, Gui XS. et al. A multimodal (FACILE) classification for optical diagnosis of inflammatory bowel disease associated neoplasia. Endoscopy 2019; 51 (02) 133-141
  • 47 Buchner AM. Endoscopic management of complex lesions in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2021; 17 (03) 121-127
  • 48 Shen B, Kochhar G, Navaneethan U. et al; Global Interventional Inflammatory Bowel Disease Group. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc 2019; 89 (02) 215-237
  • 49 Kinoshita S, Uraoka T, Nishizawa T. et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. Gastrointest Endosc 2018; 87 (04) 1079-1084
  • 50 Suzuki N, Toyonaga T, East JE. Endoscopic submucosal dissection of colitis-related dysplasia. Endoscopy 2017; 49 (12) 1237-1242
  • 51 Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994; 343 (8889): 71-74
  • 52 Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the treatment of colon cancer. Dis Colon Rectum 2017; 60 (10) 999-1017
  • 53 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114 (03) 384-413
  • 54 Maser EA, Sachar DB, Kruse D, Harpaz N, Ullman T, Bauer JJ. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn's colitis. Inflamm Bowel Dis 2013; 19 (09) 1827-1832
  • 55 Bogach J, Pond G, Eskicioglu C, Simunovic M, Seow H. Extent of surgical resection in inflammatory bowel disease associated colorectal cancer: a population-based study. J Gastrointest Surg 2021; 25 (10) 2610-2618
  • 56 Kiran RP, Nisar PJ, Goldblum JR. et al. Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection?. Ann Surg 2012; 256 (02) 221-226
  • 57 Axelrad J, Kriplani A, Ozbek U. et al. Chemotherapy tolerance and oncologic outcomes in patients with colorectal cancer with and without inflammatory bowel disease. Clin Colorectal Cancer 2017; 16 (03) e205-e210
  • 58 Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer 2017; 123 (11) 1904-1911
  • 59 Bogach J, Pond G, Eskicioglu C, Seow H. Age-related survival differences in patients with inflammatory bowel disease-associated colorectal cancer: a population-based cohort study. Inflamm Bowel Dis 2019; 25 (12) 1957-1965
  • 60 Taylor CC, Millien VO, Hou JK, Massarweh NN. Association between inflammatory bowel disease and colorectal cancer stage of disease and survival. J Surg Res 2020; 247: 77-85
  • 61 Lu C, Schardey J, Zhang T. et al. Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: a systematic review and meta-analysis. Ann Surg 2022; 276 (05) e319-e330
  • 62 Saraggi D, Fassan M, Mescoli C. et al. The molecular landscape of colitis-associated carcinogenesis. Dig Liver Dis 2017; 49 (04) 326-330
  • 63 Bojarski C, Waldner M, Rath T. et al. Innovative diagnostic endoscopy in inflammatory bowel diseases: from high-definition to molecular endoscopy. Front Med (Lausanne) 2021; 8: 655404
  • 64 The National Institute for Health and Care Excellence. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118). March 23, 2011. Accessed December 22, 2022: https://www.nice.org.uk/guidance/cg118